Bock Pharmacal/Mimetics to co-develop molecular iodine for benign fibrocystic breast disease.
BOCK PHARMACAL/MIMETICS TO CO-DEVELOP MOLECULAR IODINE for treatment of fibrocystic breast disease, Bock President William Moskoff announced Jan. 9 at the Hambrecht & Quist Life Sciences Conference in San Francisco. Under the agreement, Bock will receive exclusive marketing rights for the oral formulation in the U.S. and Canada; Mimetics will retain all manufacturing rights. The agreement includes milestone payments, royalties and research funding, Mimetics said. The companies are also in the process of closing an agreement for Bock to take a small equity stake in Mimetics.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth